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Abstract 
Background: Non-ischemic dilated cardiomyopathy (DCM) is a heterogeneous disease with 
a spectrum of etiological factors. However, subsets of the disease are not well-characterized 
with respect to these factors. The aim of this study was to evaluate the prevalence of 
myocardial inflammation and cardiotropic viruses in DCM patients and their impact on 
clinical outcome. 
Methods: Fifty-seven patients with DCM underwent endomyocardial biopsy between 2010 
and 2013. Biopsies were analyzed by polymerase chain reaction (PCR) for the presence of 
cardiotropic viruses, and inflammatory cell infiltration was assessed by 
immunohistochemistry. During a 5-year follow-up, 27 (47%) patients reached the primary 
composite outcome measure: heart transplantation, left ventricle assist device implantation or 
cardiovascular-related death. 
 2 
Results: Thirty-one (54%) patients had myocardial inflammation and cardiotropic viruses 
were detected in 29 (52%). The most frequent viruses were parvovirus B19 and human 
herpesvirus type-6. Four specific sub-groups were distinguished by PCR and 
immunohistochemistry: virus-positive (chronic) myocarditis, autoreactive inflammatory 
DCM, viral DCM, non-inflammatory DCM. The presence of a viral genome in myocardium 
or diagnosis of inflammatory DCM did not predict the outcome of composite outcome 
measures (p > 0.05). However, univariate Cox regression and survival function estimation 
revealed an association between inflammation by a high number of T-cells and poor 
prognosis. 
Conclusions: This study has shown that two markers — cardiotropic viruses and myocardial 
inflammation — are prevalent among DCM patients. They are also helpful in identifying sub-
groups of DCM. An increased number of T-lymphocytes in the myocardium is a predictor of 
poor mid-term and long‐ term prognosis. 
Key words: dilated cardiomyopathy, chronic heart failure, myocardial inflammation, 
viruses, prognosis 
 
 
Introduction 
Non-ischemic dilated cardiomyopathy (DCM) is a chronic heart disease. It presents 
with left ventricle (LV) dilatation and impaired ventricle function (left or both ventricles), 
which is not caused by coronary artery disease or abnormal loading conditions [1]. DCM is a 
heterogeneous disease with a spectrum of etiologic factors such as infectious agents, genetic 
abnormalities, autoimmune mechanisms, drugs, and toxins [2]. DCM causes heart failure, 
leading to heart transplantation or death [3]. 
Over the past few decades, the definition of DCM has developed [1, 4–6]. 
Endomyocardial biopsy, analyzed by immunohistochemistry and viral polymerase chain 
reaction (PCR), became an essential procedure for diagnosing the cause of DCM [1, 8, 9]. 
Consequently, cardiotropic viruses are recognized as a crucial etiologic factor of heart failure 
and are found in the myocardium of up to 67% of DCM patients [10, 11]. The data 
concerning the impact of the presence of cardiotropic viruses on clinical significance and 
prognosis remains under debate [12, 13].  
Diagnostic criteria for inflammation in the myocardium were updated several times 
[1, 4, 5, 7]. Myocardial inflammation, confirmed by endomyocardial biopsy, is also known as 
a significant causal factor, and is responsible for progression of LV dilatation [14–17]. 
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However, the prognostic role of myocardial inflammation on clinical outcome varies in 
different studies due to diverse diagnostic criteria [12, 18–21]. The latest definition of 
myocardial inflammation was endorsed by the European Society of Cardiology (ESC) 
Working Group on Myocardial and Pericardial Diseases [1]. However, there is a shortage of 
data, which demonstrate the prognostic relevance of myocardial inflammation defined by this 
criterion. In addition, immunohistochemistry and viral PCR are used to characterize 
etiopathogenetic subsets of DCM patients, but prospective data are lacking for these subsets. 
Thus, the clinical value of research of etiopathogenetic factors may be of paramount 
importance to prognosis assessment and may help to further the development of treatment 
strategies. 
The aim of this study was to use immunohistochemistry and PCR — to evaluate the 
prevalence of myocardial inflammation and cardiotropic viruses — in DCM patients. Further, 
to investigate their impact on the clinical outcome; and to clarify the impact of different 
myocardial inflammatory cells on mid-term and long-term prognosis.  
 
Methods 
Study population. Inclusion and exclusion criteria 
A prospective cohort study was done in the documented institution between January 2010 
and December 2013. 57 consecutive patients admitted to this institution with heart failure and 
reduced LV ejection fraction (LVEF) (with unknown etiology of LV dilatation) for diagnostic 
evaluation were enrolled. Inclusion criteria were clinical signs and symptoms of heart failure, 
accompanied by echocardiographic evidence of LV dilatation (LV end-diastolic diameter 
[LVEDD] > 117% of the predicted value, corrected for age and body surface area [> 2 
standard deviations] of the predicted normal limit +5%) and reduced (< 45%) LVEF [22, 23].  
Exclusion criteria were: 1) Significant coronary artery disease, defined as at least 50 % 
proximal stenosis of a coronary artery or a history of myocardial infarction; 2) Known causes 
of heart failure, such as primary valvular or heart muscle disease, hypertensive heart disease, 
endocrine disease, advanced renal insufficiency, drug or alcohol abuse; 3) Acute myocarditis 
(new-onset symptoms during the past three months) or acute myocardial infarction suspected 
by clinical presentation or in diagnostic testing.  
All patients provided written informed consent. Ethical approval was obtained from the 
local Lithuanian Bioethics Committee (license numbers 158200-09-382-l03; 158200-382-
PP1-23; and 158200-17-891-413).  
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All patients were treated according to the ESC guidelines [24, 25]. At the time of 
inclusion, none of the patients were treated with inotropic agents. Specific etiology-directed 
treatment was not administered.  
 
Medical examinations 
All patients underwent a medical interview, physical examination, and routine laboratory 
studies. Additionally, the proinflammatory serum cytokine interleukin-6 (IL-6) was tested as 
described elsewhere [26]. 
Echocardiography was performed for all patients to obtain conventional 
echocardiographic parameters. Cardiac magnetic resonance with late gadolinium 
enhancement was performed for 33 patients. 
Mandatory investigations included coronary angiography to exclude coronary artery 
disease, right heart catheterization for hemodynamic evaluation. During the same procedures, 
right ventricle endomyocardial biopsy was performed for the immunohistochemical 
evaluation and the detection of viruses by PCR. Three endomyocardial biopsy procedures 
were discontinued because of complications (arrhythmias or right ventricular perforation). 
Due to the lack of biopsy samples, PCR was performed for two of the above-mentioned 
patients and immunohistochemical analysis for one. 
 
Histological and immunohistochemical assessment 
Storage of the endomyocardial biopsy samples, and histological and 
immunohistochemical analyses were performed as described previously [26]. In brief, we 
detected antibodies (Santa Cruz Biotechnology, Inc.) against: T-lymphocyte CD3 (DAKO 
A0452 Rabbit 1, Hamburg, Germany), active-memory T-lymphocyte CD45Ro (DAKO 
Hamburg), macrophage CD68 (DAKO M0876 Mouse 1, Hamburg), T-helper cell CD4 
(DAKO Hamburg, Germany), intracellular adhesion molecule-1 (ICAM-1) CD54 
(NovocastraTM Lyophilized Mouse Monoclonal Antibody CD54 Clone 23G12), and MHC 
class II cell surface receptor HLA-DR (DAKO Hamburg, Germany). Positive cells were 
registered by an experienced pathologist and expressed as the number of cells per mm2.  
Myocardial inflammation was diagnosed according to the criterion established by the ESC 
Working Group on Myocardial and Pericardial Diseases. This criterion is 
immunohistochemical detection of significant focal or diffuse cellular infiltration in the 
endomyocardial biopsy (≥ 14 leucocytes/mm2, including up to 4 monocytes/mm2 with the 
presence of CD3 positive T-lymphocytes ≥ 7 cells/mm2) [1]. Inflammatory endothelial 
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activation was diagnosed if immunohistochemical analysis revealed ≥ 3 cells expressing 
adhesion molecules, i.e., ICAM-1 (CD54) and/or HLA-DR [27]. 
 
Detection of viral genomes  
 Genomic DNA and total RNA were extracted simultaneously using the ZR-Duet 
DNA/RNA Miniprep kit (Zymo Research, Irvine, CA, USA). RNA (1 µg) was reverse 
transcribed in 20 µL reaction volumes using random hexamers and the First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific, Vilnius, Lithuania) according to the vendor’s 
recommendations and diluted up to 100 µL with deionized water after the reaction.  
Nested PCR primers for the detection of adenovirus [28], herpes simplex viruses 1 and 
2, varicella-zoster virus (VZV), cytomegalovirus (CMV), parvovirus B19 (B19V), Epstein-
Barr virus (EBV), hepatitis C virus (HCV), enterovirus (EV), and rubella virus [29] are 
described elsewhere. Primer sequences for the nested PCR of human herpes virus 6 (HHV-6, 
GenBank accession no. NC001664.2 and NC000898.1); Kirsten rat sarcoma viral oncogene 
homolog (KRAS, GenBank accession no. NM033360); and ubiquitin C (UBC, GenBank 
accession no. NM021009) are presented in Table 1. Forward primers for the second PCR step 
(N2Fw) were labeled with 6-carboxyfluorescein at the 5’ end. All primers were synthesized 
by the Metabion Company (Martinsried, Germany).  
All PCRs were run on a TProfessional Standard thermocycler (Biometra, Göttingen, 
Germany), as described by Allard et al. [28]. KRAS and UBC detection was used to validate 
the extraction of nucleic acids and was performed in parallel according to the conditions for 
viral DNA and RNR, respectively. Final PCR products were diluted 10-fold and sized by 
capillary electrophoresis on a Genetic Analyzer 3130xl, using GeneScan 600 LIZ™ Size 
Standard and Gene Mapper Software v4.1 (Applied Biosystems, Foster City, CA, USA). For 
positive results, the genomic DNA or RNR specimens from peripheral blood samples were 
also tested to exclude contamination. 
 
Follow-up 
All patients were followed-up for 5 years after the endomyocardial biopsy. The 
composite outcome measures were composite and combined three outcomes: cardiovascular 
death, LV assist device (LVAD) implantation, or heart transplantation. The time of the first 
event was the endpoint of the follow-up. Follow-up events were confirmed by medical 
records or telephone interview with the patients’ families. 
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Statistical analysis 
Data management and analysis were performed using the R studio package (3.5.1 
version) at a 5% significance level. Continuous variables were tested by the Shapiro-Wilk 
statistic for normal distribution. Normally distributed continuous variables were expressed as 
the mean ± standard deviation. Other continuous variables were expressed as the median 
(interquartile range), and categorical data as counts and percentages. Continuous variables 
were compared by the Student independent t-test when normally distributed, or by the Mann-
Whitney-U test when non-normally distributed. Comparisons of categorical variables 
between the groups were made using the chi-square test or the Fisher Exact test if expected 
values were < 5.  
Univariate Cox proportional hazards regression analysis was performed to evaluate 
which inflammatory cells or clinical parameters were associated with poor mid-term and 
long-term outcome (composite outcome measures) after 2-year and 5-year follow-up. The 
optimal cut-off point was determined using the receiver operating characteristic (ROC) curve. 
The Kaplan-Meier analysis was used to compare cumulative survival rates between different 
subgroups of DCM patients after a 2-year and 5-year follow-up. The log-rank statistic was 
used to evaluate the statistical significance of differences between curves. 
 
Results 
Baseline patients’ characteristics 
Fifty-seven DCM patients (mean age 47.3 ± 10.9 years; 45 [79%] males) with chronic 
heart failure participated in the study. The average LVEDD was 6.8 ± 0.9 cm, average LVEF 
— 26.08 ± 9.5%, and average pulmonary artery wedge pressure — 21.8 ± 8.9 mmHg. Of 
these patients, 41 (72%) were New York Heart Association (NYHA) III class and 10 (17%) 
were NYHA IV class. The median (interquartile range) heart failure duration was 12 (55) 
months. Baseline characteristics are shown in Table 2.  
Of the 57 patients, 27 (47%) reached the composite outcome measure during the 5-
year follow-up period: 10 (18%) patients died; 9 (16%) underwent heart transplantation, and 
8 (14 %) LVAD implantation. Other patients remained on conventional medical heart-failure 
therapy. The 5-year cumulative survival rate was 53%. In univariate Cox regression models, 
most hemodynamic parameters, echocardiographic parameters and IL-6 were associated with 
poor clinical outcomes (Table 2). 
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The prevalence of cardiac inflammation 
Immunohistochemical analysis was performed on 55 endomyocardial biopsies. 
Myocardial inflammation was detected in 31 of the 55 (54%) DCM patients. Patients were 
divided into two groups: inflammatory DCM (iDCM) and non-inflammatory DCM (non-
iDCM).  No difference was observed in baseline characteristics of the two groups (p > 0.05; 
Table 2), except for lower systolic blood pressure and higher level of B-type natriuretic 
peptide in the iDCM group (p ≤ 0.05). 
Kaplan-Meier analysis showed no difference between survival curves of patients with 
iDCM and non-iDCM (p > 0.05; Fig. 1). 
However, univariate Cox regression analysis revealed an association between a higher 
CD45ro+ cell count in the myocardium and poor mid‐ term prognosis. Higher CD3+ cell 
count in the myocardium was associated with poor mid-term and long-term prognosis. This 
was not the case for CD68+ inflammatory infiltrative cells (Table 3). ROC curves determined 
the cut-off values for CD3+ and CD45ro+ cells (Fig. 2). The cohort was divided into two 
groups according to whether their CD3+ and CD45ro+ cell counts were above or below the 
cut‐ off value (13 cells/mm2 and 11.5 cells/mm2, respectively). Univariate Cox regression 
analysis showed that cell counts above cut-off values were associated with worse mid-term 
and long-term clinical outcome (Table 3). Estimation of survival curves demonstrated that 
patients with CD3+ and CD45ro+ cell counts above the cut-off values had lower survival 
rates (Fig. 3). Lower p-values in survival analysis and higher HR (95% confidence interval 
[CI]) in Cox regression analysis revealed that inflammatory cells predict better mid-term than 
long-term outcomes. 
Inflammatory endothelial activation (increased expression of HLA-DR and ICAM [≥ 3 
cells/mm2]) was detected by immunohistochemistry in 50 (91%) patients. The expression did 
not, however, differ between the iDCM and non-iDCM groups (p > 0.05). However, it should 
be interpreted with caution, while these proteins are not only markers for endothelial 
activation, but are also found on the surface of immune cells. 
 
Prevalence of cardiotropic viruses 
Polymerase chain reaction analysis was performed on 56 endomyocardial biopsies. Viral 
genomes were detected in the myocardium of 29 (52%) of the 56 DCM patients. Of these 29 
patients, 25 (86%) had the B19V genome, and other 5 (17%) had HHV6 genome. Other 
viruses (VZV, CMV, EBV, HCV, EV), were detected in single cases (n = 1 [3%] of each 
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type). Three (10%) of virus-positive patients had a double infection and one of them (3%) a 
triple infection. Co-detection of B19V and HHV6 prevailed (n = 3 [10%]).  
The remaining 27 (48%) patients were virus-negative. There were no differences in most 
baseline parameters between the virus-positive and virus-negative groups (p > 0.05), except 
for higher B-type natriuretic peptide and IL-6 levels, worse hemodynamic parameters (Table 
2), and a higher number of infiltrative CD68+ cells in the virus-negative group (Fig. 4). 
Kaplan-Meier survival curves demonstrated no difference in survival rates of patients in 
virus-positive and virus-negative groups (p > 0.05; Fig. 5). 
   
Sub-groups of idiopathic DCM 
Both PCR analysis and immunohistochemical evaluation were performed on 54 DCM 
patients. Based on the detection of viral genome — in combination with positive or negative 
immunohistochemistry — four specific sub-groups of patients were distinguished: 
— Virus-positive (chronic) myocarditis (15 [28%] patients): both cardiotropic virus and 
myocardial inflammation is present; 
— Autoreactive iDCM (16 (30%) patients): no cardiotropic virus was detected but 
myocardial inflammation was present; 
— Viral DCM (14 (26 %) patients): viral genome was detected but no signs of 
myocardial inflammation; 
— Non-inflammatory DCM (9 [17%] patients): neither viral genome nor inflammation 
was detected. 
 
Discussion 
This prospective study summarizes an experience identifying etiopathogenetic markers of 
idiopathic DCM for diagnosis of distinct disease sub-entities, and evaluates their prognostic 
value. In this study, The criterion defined by the ESC Working Group on Myocardial and 
Pericardial Diseases [1] for diagnosing iDCM was used. iDCM was diagnosed in 54% of the 
patients by immunohistochemistry. The rate of the iDCM was similar when compared to the 
study by Palecek et al. [30]. The prognostic value of myocardial inflammation and different 
inflammatory cells varies in different studies, possibly due to the diversity of diagnostic 
protocols [31]. Though, according to available research, there no study which evaluated the 
prognostic value of iDCM diagnosed by ESC criterion. In the present cohort, iDCM had no 
impact on clinical outcomes. However, a higher count of CD3+ and CD45ro+ cells were 
associated with a poor clinical outcome.  
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The current study found a high prevalence of cardiotropic viruses (52% of patients), of 
which the most frequently detected were B19V and HHV6. Three (10%) patients were co-
infected with B19V and HHV6. These findings support previous studies, in which B19V and 
HHV6 were the most frequent viruses [10, 32, 33]. Furthermore, the high prevalence of 
B19V suggests that chronic DCM might have developed from the previous B19V-associated 
myocarditis [34]. However, there is conflicting evidence about the viral genome’s impact on 
the long-term prognosis. Several studies revealed that viral genomes were associated with 
worsening LV function, the need for heart transplantation, and death [10, 35]. While other 
studies report that the existence of viral genomes per se is not associated with poor clinical 
outcome [12, 36–38]. In the present cohort, detection of a virus had no impact on clinical 
outcome.  
However, half of the virus-positive patients had no myocardial inflammation. This 
finding is also reported by Kuehl et al., in whose study DCM patients had symptoms of heart 
failure and viral genome, but no evidence of inflammation [10, 35]. Kindermann et al. [12] 
have also reported that the frequency of inflammation is independent of any evidence of the 
virus genome. Several studies detected B19V in healthy people’s hearts with no evidence of 
inflammation [38–40]. 
In contrast, half of the current iDCM patients had no viral genome, and cause of 
inflammation remains unknown. This finding supports the idea that myocardial inflammation 
could be maintained by an autoimmune process leading to the deterioration of LV function 
[41]. Contrarily, this high prevalence of cardiac inflammation might be due to the advanced 
DCM phenotype. The question remains whether this inflammation is a consequence of this 
advanced stadium or if it acts as a causal factor. 
Interestingly, the macrophage count was higher in the virus-negative group. It could be 
hypothesized that CD68+ macrophages have an impact on DCM pathogenesis because of 
their pro-inflammatory activity. As known from previous studies, macrophages can cause or 
maintain persistent LV systolic dysfunction and LV remodeling [42]. While recent studies 
have noted the importance of macrophage profiles and their function in heart diseases, much 
is still unknown about their impact on DCM pathogenesis [43]. 
Virus-negative patients had worse hemodynamic parameters and higher B-type natriuretic 
peptide levels than the virus-positive patients, although echocardiographic parameters did not 
differ between the two groups. Worse hemodynamic status might be explained by chronic 
immune activation and myocardial inflammation, given that higher numbers of macrophages 
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and higher levels of IL-6 were detected in this virus-negative group. Macrophages secrete IL-
6 [44], which might increase the severity of pulmonary hypertension [45].  
Although heart failure treatment has become more effective, there are still many 
refractory DCM patients who do not respond to any available treatment. Therefore, 
developing alternative therapies is essential. Four etiopathogenetic groups were 
distinguished, for whom  the specific therapeutic strategy selected could be suitable [1, 6, 46] 
or novel treatment options established [13]. Treatment strategies based on the 
etiopathogenetic approach to the disease might improve LV function, prevent progression of 
heart failure, and, in some cases, exclude patients from the heart transplant list. 
 
Limitations of the study 
First, small sample size did not allow for differentiation of patients based on the type of 
infectious agent. Second, the study had no control group, due to a shortage of healthy donor 
hearts which were not suitable for transplantation. Third, as a result of financial 
considerations, we neither virus replication nor the viral load for distinguishing active from 
incidental infection were investigated [47], nor was autoantibody testing performed or genetic 
screening for pathogenic DCM mutations. Fourth, due to limited experience in specific DCM 
treatment and the treatment costs, none of the patients received etiology-directed treatment. 
Finally, the study was held at a time when right ventricle was a “forgotten” ventricle, 
therefore it was limitedly assessed. In spite of its limitations, the study certainly provides a 
basis for a more extensive diagnostic and treatment studies — based on etiopathogenetic sub-
entities which include a control group.  
 
Conclusions 
This study has shown that two markers, cardiotropic viruses and myocardial 
inflammation, are prevalent among DCM patients and are helpful in identifying sub-groups 
of DCMs. An increased number of T-lymphocytes in the myocardium is a predictor of poor 
mid-term and long‐ term prognosis. The finding of specific inflammatory cells as a 
prognostic marker could be of value in determining new definitions of cardiac inflammation. 
A natural continuation of this work would be further analysis of specific etiologic DCM sub-
groups and a search for etiology-directed treatment strategies. 
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Table 1. Primers for detection of human herpes virus 6 (HHV6), Kirsten rat sarcoma viral oncogene 
homolog (KRAS) and ubiquitin C (UBC). 
Primer Sequence (5’–3’) 
HHV6-N1 Forward  ACCCGAGAGATGATTTTGCGTG 
HHV6-N1 Reverse GCAGAAGACAGCAGCGAGATAG 
HHV6-N2 Forward CATAGCAACCTTTTCTAGCTTTGAC 
HHV6-N2 Reverse TCTATAACATAAATGACCCCTGGGA 
UBC-N1 Forward  TTCTTTCCAGAGAGCCGAAC 
UBC-N1 Reverse CCCATCTTCCAGCTGTTTTC 
UBC-N2 Forward TGGGTCGCAGTTCTTGTTTG 
UBC-N2 Reverse  CCTTCCTTATCTTGGATCTTTGCC 
KRAS-N1 Forward CTTTGGAGCAGGAACAATGTCT 
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KRAS-N2 Forward  AATCCAGACTGTGTTTCTCCCT 
KRAS-N1/N2 Reverse TACACAAAGAAAGCCCTCCCC 
 
 
Table 2. Baseline characteristics for the study population. A comparison of baseline 
characteristics of non-inflammatory dilated cardiomyopathy (non-iDCM) and inflammatory 
dilated cardiomyopathy (iDCM) patients, and patients with and without the viral genome. 
Univariate Cox analysis showing the association between the various clinical parameters and 
poor long-term clinical outcome. 
Variable All 
patients 
(n = 57) 
Non-
iDCM (n 
= 24) 
iDCM (n 
= 31) 
P Virus-
negative 
(n = 27) 
Virus-
positive 
(n = 29) 
P HR (95% 
CI) 
P 
Clinical characteristics 
Age, years 47.3 ± 
10.9 
48.3 ± 13 46.6 ± 9,6 0.58 48.44 ± 
12.68 
46.07 ± 
9.28 
0.43 0.98 (0.95–
1.01) 
0.26 
Male gender 45 (79%) 17 (71%) 26 (82%) 0.25 23 (85%) 21 (72%) 0.23 1.41 (0.53–
3.73) 
0.49 
BMI [kg/m2] 26.84 
(8.13%) 
27.3 
(8.2%) 
25.7 (8%) 0.45 28.1 
(7.2%) 
25.2 
(8.7%) 
0.24 0.98 (0.91–
1.05) 
0.54 
Systolic BP 
[mmHg] 
116 ± 20 123 ± 20 110 ± 17 0.01 115 ± 20 118 ± 22 0.63 0.97 (0.95–
0.99) 
0.002 
Diastolic BP 
[mmHg] 
80 (10%) 78 (13%) 80 (10%) 0.43 80 (10%) 80 (10%) 0.76 0.96 (0.92–
0.99) 
0.02 
Heart rate [bpm] 77 (27%) 73 (22%) 86 (32%) 0.18 79 (23%) 76 (34%) 0.83 1.01 (0.99–
1.03) 
0.35 
Atrial fibrillation 11 (19%) 3 (13%) 8 (26%) 0.31 6 (22%) 5 (17%) 0.64 0.95 (0.36–
2.52) 
0.92 
LBBB 14 (25%) 6 (25%) 8 (26%) 0.99 10 (37%) 4 (14%) 0.15 1.66 (0.72–
3.79) 
0.23 
NYHA III–IV class 51 (90%) 20 (83%) 29 (94%) 0.64 24 (89%) 26 (90%) 1 4 (0.54–
29.53) 
0.17 
Follow-up time 
[months] 
60 (37%) 60 (32%) 60 (47%) 0.4 48 (46%) 60 (15%) 0.14   
Biomarkers/blood testing 
Hemoglobin [g/L] 142 ± 16 137.7 ± 
13.7 
144.7 ± 
14.7 
0.08 142.7 
±16.6 
141.3 
±14.6 
0.73 1 (0.98–
1.02) 
0.72 
eGFR 
[mL/min/1.73 m2] 
111 ± 30 104 ± 31 116 ± 30 0.17 109 ± 28 110 ± 31 0.87 1 (0.99–
1.02) 
0.43 
BNP [ng/L] 728 
(1797%) 
214 
(1445%) 
1017 
(2432%) 
0.05 916 
(2571%) 
228 
(1329%) 
0.04 1 (1–1) 0.12 
CRP [mg/L] 4.6 
(14.2%) 
5.2 (6.6%) 4.5 
(15.3%) 
0.74 6.6 
(13.5%) 
2.4 
(10.3%) 
0.12 1 (0.98–
1.03) 
0.72 
IL-6 [pg/mL] 2.5 (4.7%) 2.2 (3.1%) 2.9 (7.4%) 0.21 4.62 
(6.3%) 
2.01 
(2.6%) 
0.04 1.04 (1.01–
1.06) 
0.004 
Echocardiographic parameters  
LVEF [%] 26.08 ± 
9.5 
25.6 ±11.8 26.7 ±7.1 0.69 26.9 ± 9.2 26.7 ± 
9.9 
0.94 0.93 (0.89–
0.98) 
0.004 
LVEDD [cm] 6.8 ± 0.9 6.8 ± 0.9 6.9 ± 0.9 0.57 7.0 ± 0.9 6.7 ± 0.8 0.12 1.49 (0.94–
2.36) 
0.09 
LV diastolic 
function (n = 54): 
         
Grade I 14 (26%) 7 (30%) 7 (23%) 0.79 6 (22%) 9 (33%) 0.61   
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Grade II 16 (30%) 6 (26%) 10 (33%) 8 (30%) 8 (30%) 1.32 (0.44–
3.93) 
0.62 
Grade III 23 (43%) 10 (44%) 13 (43%) 13 (48%) 10 (37%) 2.4 (1.15–
6.07) 
0.02 
Functional mitral 
regurgitation ≥ 
moderate, n (%)* 
32 (56%) 13 (54%) 19 (61%) 0.6 17 (63%) 14 (48%) 0.27 2.4 (1.08–
5.33) 
0.03 
RV end-diastolic 
diameter [cm] 
3.3 ± 0.6 3.2 ± 0.8 3.4 ± 0.5 0.3 3.4 ± 0.6 3.3 ± 0.6 0.63 2.75 (1.56–
4.84) 
<0.001 
RV systolic 
function:* 
         
Normal 21 (37%) 11 (46%) 9 (29%) 0.11 6 (22%) 15 (52%) 0.13   
Mildly impaired 9 (16%) 4 (17%) 5 (16%) 5 (19%) 4 (14%) 2.04 (0.6–
6.41) 
0.23 
Moderately 
impaired 
11 (19%) 1 (4%) 9 (29%) 6 (22%) 5 (17%) 1.72 (0.55–
5.4) 
0.35 
Severely impaired 16 (28%) 8 (33%) 8 (26%) 10 (37%) 5 (17%) 3.67 (1.42–
9.53) 
0.008 
TAPSE (n = 33) 15 (6.3%) 15 (5.5%) 13 (5.5%) 0.64 15 (4.5%) 16 
(5.5%) 
0.83 0.7 (0.56–
0.87) 
0.001 
Functional tricuspid 
regurgitation ≥ 
moderate, n (%)* 
20 (35%) 9 (38%) 11 (36%) 0.88 11 (41%) 9 (31%) 0.45 2.98 (1.41–
6.3) 
0.004 
Cardiac magnetic resonance 
Mid-wall late 
gadolinium 
enhancement (n = 
33) 
22 (73%) 7 (54%) 14 (78%) 0.25 10 (72%) 11 (61%) 0.71 1.59 (0.44–
5.78) 
0.48 
Hemodynamic measurements (n = 54) 
PAWP [mmHg] 21.8 ± 8.9 21.5 ± 9.6 22.6 ± 8.8 0.65 25 ± 9 19 ± 8 0.02 1.07 (1.02–
1.12) 
0.004 
Mean RAP 
[mmHg] 
11 (6.5%) 10 (6%) 11 (10%) 0.96 12 (8%) 8 (8%) 0.09 1.07 (1.02–
1.13) 
0.007 
Mean PAP [mmHg] 29 ± 18 31 ± 12 32 ± 11 0.67 35 ± 11 28 ± 9 0.02 1.05 (1.02–
1.09) 
0.005 
PVR [mmHg] 2 (2%) 1.5 (1.6%) 2.3 (1.6%) 0.08 2.4 
(2.7%) 
1.6 
(1.4%) 
0.04 1.22 (1–
1.49) 
0.05 
Pulmonary 
hypertension 
36 (68%) 14 (60%) 21 (75%) 0.28 18 (72%) 17 (63%) 0.49 3.37 (1.15–
9.9) 
0.03 
Concomitant cardiac medication 
ACE-I/ARB 41 (72%) 18 (75%) 18 (58%) 0.19 15 (56%) 22 (76%) 0.11 0.99 (0.44–
2.19) 
0.97 
Beta-blocker 54 (95%) 24 (100%) 28 (90%) 0.25 24 (89%) 29 
(100%) 
0.11 0.42 (0.1–
1.79) 
0.24 
MRA 51 (90%) 20 (83%) 30 (97%) 0.16 26 (96%) 24 (83%) 0.2  0.99 
Diuretics 53 (93%) 21 (88%) 30 (97%) 0.31 25 (93%) 27 (93%) 1 2.46 (0.33–
18) 
0.38 
Virus-positive endomyocardial biopsies 
Total  15 (63%) 14 (47%) 0.25 0 29 (52%)  0.64 (0.3–
1.39) 
0.26 
B19V  13 (54%) 12 (40%) 0.3 0 25 (45%)    
EBV  0 (0%) 1 (3%) 1 0 1 (2%)    
EV  0 (0%) 1 (3%) 1 0 1 (2%)    
HHV-6  2 (8%) 3 (10%) 1 0 5 (9%)    
VZV  1 (4%) 0 (0%) 0.44 0 1 (2%)    
HCV  0 (0%) 1 (3%) 1 0 1 (2%)    
Immunohistological markers of endothelial activation (n = 55) 
ICAM-1/CD54+ 
[cells/mm2] 
0 (1%) 0 (1%) 0 (1.5%) 0.45 0 (2%) 0 (1%) 0.26   
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HLA DR 
[cells/mm2] 
5 (2%) 4.5 (2%) 5.0 (2%) 0.1 5 (1%) 5 (2%) 0.23   
CD3+ [cells/mm2] 10 (9%) 7 (2%) 15 (8%) < 
0.001 
10 (9%) 9 (5%) 0.66   
CD45+ [cells/mm2] 7 (5%) 5 (2%) 10 (6%) < 
0.001 
7 (5%) 6 (3%) 0.42   
CD68+ [cells/mm2] 4 (2%) 3 (2%) 5 (4%) < 
0.001 
5 (3%) 3 (3%) 0.01   
*Evaluated via “eyeballing”. Values are expressed as: median (interquartile range), mean ± standard deviation or number (%); hazard ratio 
(HR) and 95% confidence interval (CI). The p values in bold indicate a value < 0.05; BMI — body mass index; BP — blood pressure; 
LBBB — left bundle branch block; NYHA — New York Heart Association; eGFR — estimated glomerular filtration rate; BNP — B type 
natriuretic peptide; CRP — C-reactive protein; IL-6 — interleukin 6; LVEF — left ventricular ejection fraction; LVEDD — left ventricular 
end-diastolic diameter; LV — left ventricle; RV — right ventricle; TAPSE — tricuspid annular plane systolic excursion, PAWP — 
pulmonary capillary wedge pressure; RAP — right atrial pressure; PAP — pulmonary arterial pressure; PVR — pulmonary vascular 
resistance. ACE-I — angiotensin-converting enzyme inhibitor, ARB — angiotensin II receptor blocker, MRA — mineralocorticoid receptor 
antagonist; B19V — parvovirus B19; EBV — Epstein-Barr virus; EV — enterovirus; HHV-6 — human herpes virus 6; VZV — varicella 
zoster virus; HCV — hepatitis C virus 
 
 
Table 3. Univariate Cox univariate analysis showing the association between the number of myocardial 
inflammatory infiltrates and poor clinical outcome after 2-year and 5-year follow-up. 
Cardiac inflammatory 
infiltration and endothelial 
activation markers [cells/mm2] 
HR (95% CI) 
After 2-year follow-
up 
P After 5-year follow-
up 
P 
CD3+  1.085 (1.04–1.132) < 0.001 1.061 (1.02–1.103) 0.003 
CD45ro+ 1.079 (1.025–1.136) 0.004 1.048 (0.998–1.101) 0.06 
CD68+   1.075 (0.862–1.34) 0.523 1.029 (0.867–1.223) 0.74 
CD4+  1.01 (0.91–1.13) 0.82 1.013 (0.908–0.13) 0.82 
CD54+ 0.82 (0.53–1.25) 0.35 0.816 (0.532–1.254) 0.35 
HLA-DR+ 1.02 (0.91–1.14) 0.7 1.022 (0.915–1.143) 0.7 
CD3+ ≥ 13 cells/mm2 4.481 (1.588–12.64) 0.005 2.181 (1.009–4.711) 0.047 
CD45ro+ ≥ 11.5 cells/mm2 5.261 (1.854–14.93) 0.002 2.892 (1.217–6.871) 0.016 
Values are expressed as hazard ratio (HR) and 95% confidence interval (CI). The p values in bold 
indicate a value < 0.05. 
 
 
Figure 1. Kaplan-Meier analysis of the inflammatory dilated cardiomyopathy (iDCM) and 
non-inflammatory dilated cardiomyopathy (non-iDCM) groups. 
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Figure 2. Receiver operating characteristic curve analysis of CD3+ and CD45ro+ cells for 
predicting composite endpoint. The best cut-off values were 13 CD3+ cells/mm2 (sensitivity, 
41%; specificity, 75%) and 11.5 CD45ro+ cells/mm2 (sensitivity, 26%; specificity, 89%). 
 
Figure 3. Survival curves according to the count of CD3+ and CD45ro+ cells. Patient groups 
with a higher number of infiltrative cells (CD3+ >13 cells/mm2 and CD45ro+ > 11.5 
cells/mm2) had a significantly lower survival rate than groups with lower cell counts. 
 
Figure 4. Comparison of inflammatory cell (CD3+, CD45ro+, and CD68+) counts in the 
virus-negative and virus-positive biopsies. 
 
Figure 5. The Kaplan-Meier curves for virus-positive and virus-negative groups 
 





